医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2015年
3期
62-63
,共2页
吡柔比星%化疗%老年%恶性淋巴瘤%安全性
吡柔比星%化療%老年%噁性淋巴瘤%安全性
필유비성%화료%노년%악성림파류%안전성
Pyrazole soft than star%Chemotherapy%Old age%Malignant lymphoma%Security
目的：探讨吡柔比星辅助化疗方案治疗老年人恶性淋巴瘤的疗效及安全性。方法：选取91例老年恶性淋巴瘤患者为研究对象，根据患者意愿分成联合组（A组，n=50）和化疗组（B组，n=41）两组。比对两组患者临床疗效及不良反应发生情况。结果：①治疗后，A组总有效率为84.0%，明显高于B组的53.7%，对比差异明显（P<0.05）；②A组不良反应发生率为40.0%，明显低于B组的63.4%，对比差异明显（P<0.05）。结论：对老年恶性淋巴瘤患者予以吡柔比星辅助化疗方案，疗效确切，值得临床推广。
目的：探討吡柔比星輔助化療方案治療老年人噁性淋巴瘤的療效及安全性。方法：選取91例老年噁性淋巴瘤患者為研究對象，根據患者意願分成聯閤組（A組，n=50）和化療組（B組，n=41）兩組。比對兩組患者臨床療效及不良反應髮生情況。結果：①治療後，A組總有效率為84.0%，明顯高于B組的53.7%，對比差異明顯（P<0.05）；②A組不良反應髮生率為40.0%，明顯低于B組的63.4%，對比差異明顯（P<0.05）。結論：對老年噁性淋巴瘤患者予以吡柔比星輔助化療方案，療效確切，值得臨床推廣。
목적：탐토필유비성보조화료방안치료노년인악성림파류적료효급안전성。방법：선취91례노년악성림파류환자위연구대상，근거환자의원분성연합조（A조，n=50）화화료조（B조，n=41）량조。비대량조환자림상료효급불량반응발생정황。결과：①치료후，A조총유효솔위84.0%，명현고우B조적53.7%，대비차이명현（P<0.05）；②A조불량반응발생솔위40.0%，명현저우B조적63.4%，대비차이명현（P<0.05）。결론：대노년악성림파류환자여이필유비성보조화료방안，료효학절，치득림상추엄。
Objective Explore pyrazole soft than star adjuvant chemotherapy regimen for the elderly efficacy and safety of malignant lymphoma.Methods Select 91 cases senile patients with malignant lymphoma as the research object, according to their willingness to into joint group (group A, n = 50) and chemotherapy group (group B, n = 41) in the two groups. Compare two groups of patients with clinical efficacy and adverse reactions occur.Results (1) after treatment, the total effective rate of group A was 84.0%, significantly higher than the 53.7% of the group B, compared with significant difference (P<0.05); (2) the incidence of adverse reaction of group A was 40.0%, significantly less than 63.4% of the group B, compared with significant difference (P<0.05).Conclusion Pyrazole soft to elderly patients with malignant lymphoma than star adjuvant chemotherapy scheme, curative effect, worth clinical promotion.
